Pre-Tax Income: Company's earnings or loss before taxes on income have been accounted for.
SAB Biotherapeutics, Inc. (SABS) had Pre-Tax Income of $-10.11M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-10.11M |
|
-- |
|
-- |
|
$9.73M |
|
$-9.73M |
|
$-0.38M |
|
|
Pre-Tax Income |
$-10.11M |
$-10.11M |
|
$-10.11M |
|
$-10.11M |
|
$-10.11M |
|
$-10.11M |
|
$-9.73M |
|
$-8.97M |
|
9.29M |
|
9.29M |
|
$-1.09 |
|
$-1.09 |
|
| Balance Sheet Financials | |
$9.31M |
|
$13.86M |
|
$20.82M |
|
$30.13M |
|
$10.68M |
|
$3.20M |
|
$7.44M |
|
$18.11M |
|
$12.02M |
|
$12.02M |
|
$12.02M |
|
9.29M |
|
| Cash Flow Statement Financials | |
$-14.95M |
|
$9.87M |
|
$-0.35M |
|
$8.90M |
|
$3.69M |
|
$-5.21M |
|
$1.24M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.87 |
|
-- |
|
-- |
|
0.21 |
|
0.28 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-14.95M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-84.17% |
|
-84.17% |
|
-33.57% |
|
-66.47% |
|
$1.29 |
|
$-1.61 |
|
$-1.61 |
|